Impel NeuroPharma was founded with a mission to enable drugs to bypass the blood brain barrier. Co-founders John Hoekman, Ph.D., and Michael Hite began their work together in 2008 at the University of Washington, and developed a technical concept into an enabling, commercializable technology.
Their innovations have materialized into a rapidly growing medical device company that has attracted seasoned professionals committed to developing a robust technology platform for nose-to-brain drug delivery. In addition to pioneering technical achievements, Impel’s comprehensive approach to design also considers patient comfort, regulatory approval pathways, and cost effectiveness. Collectively, these innovations accelerate the realization of new drug therapies for the treatment of many central nervous system diseases.